[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563321":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":41,"centralContacts":58,"locations":67,"responsibleParty":188,"collaborators":191,"id":208,"slug":209,"hasResults":210,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":210,"sex":216,"minAge":217,"maxAge":21,"enrollmentInfo":218,"targetDuration":21,"studyType":221,"phases":222,"briefSummary":224,"conditions":225,"keywords":229,"overallStatus":70,"whyStopped":21,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":242},{"fullName":5,"class":6},"University of Aarhus","OTHER",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention group (IG)","EXPERIMENTAL","Patients with curatively resected stage I or low risk stage II colorectal cancer, residing in Central or North region, Denmark.",[13,14,15,16],"Diagnostic Test: Recurrence monitoring with circulating tumor DNA (ctDNA) as a high risk biomarker","Behavioral: Monitoring for late adverse effects with electronic patient reported outcome measures (ePROMs)","Behavioral: Systematic treatment of organ-specific late effects and\u002For biopsychosocial late effects","Behavioral: Digital care-guide for long-term follow-up after cancer treatment",{"label":18,"type":19,"description":20,"interventionNames":21},"Standard-of-care group (SG)","NO_INTERVENTION","Patients with curatively resected stage I or low risk stage II colorectal cancer, residing in South or Capital region, Denmark.",null,[23,28,33,37],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":21},"DIAGNOSTIC_TEST","Recurrence monitoring with circulating tumor DNA (ctDNA) as a high risk biomarker","IG patients will receive the following intervention at 3, 12, 24, and 36 months post-surgery:\n\n1\\) Recurrence risk stratification by ctDNA analysis of blood samples:\n\na) Only if ctDNA becomes positive, will imaging be performed. b) If ctDNA is positive, but recurrent disease is not detected by imaging or clinical and endoscopic evaluation, the patient will be referred back to intensified ctDNA measurements repeated every 4 months until either ctDNA becomes negative or recurrence is confirmed by subsequent imaging.",[9],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":21},"BEHAVIORAL","Monitoring for late adverse effects with electronic patient reported outcome measures (ePROMs)","2\\) Collection and analyses of ePROMs to identify whether patients suffer from organ-specific late effects or biopsychosocial late effects and monitor of health related quality of life and the impact of late adverse effects hereon.",[9],{"type":29,"name":34,"description":35,"armGroupLabels":36,"otherNames":21},"Systematic treatment of organ-specific late effects and\u002For biopsychosocial late effects","3\\) When needed, standardized treatment for organ-specific late effects according to newly published national guidelines at specialized centers. Further, online cognitive behavioral therapy is offered to patients suffering from severe biopsychosocial late effects.",[9],{"type":29,"name":38,"description":39,"armGroupLabels":40,"otherNames":21},"Digital care-guide for long-term follow-up after cancer treatment","Use of a digital care-guide from study inclusion to guide the patient trough the follow-up program, in the form of a personalized smart phone app.",[9],[42,45,48,51,53,56],{"name":43,"affiliation":5,"role":44},"Lene H Iversen, Prof.","PRINCIPAL_INVESTIGATOR",{"name":46,"affiliation":47,"role":44},"Peter Christensen, Prof.","Aarhus University Hospital",{"name":49,"affiliation":50,"role":44},"Ole Thorlacius-Ussing, Prof.","Aalborg University Hospital",{"name":52,"affiliation":47,"role":44},"Robert Zacchariae, Prof.",{"name":54,"affiliation":55,"role":44},"Liza Sopina, Ass.Prof.","University of Southern Denmark",{"name":57,"affiliation":5,"role":44},"Claus L Andersen, Prof.",[59,63],{"name":57,"role":60,"phone":61,"phoneExt":21,"email":62},"CONTACT","+45 78455319","cla@clin.au.dk",{"name":64,"role":60,"phone":65,"phoneExt":21,"email":66},"Mai-Britt W Ørntoft, Ass. Prof.","+45 78432424","mwo@clin.au.dk",[68,86,99,112,126,137,149,162,175],{"facility":69,"status":70,"city":71,"state":72,"zip":73,"country":74,"countryCode":75,"cosmosGeoPoint":76,"geoPoint":81,"contacts":82},"Gødstrup Hospital","RECRUITING","Herning","Central Jutland","7400","Denmark","DK",{"type":77,"coordinates":78},"Point",[79,80],8.97662,56.13615,{"lat":80,"lon":79},[83],{"name":84,"role":60,"phone":21,"phoneExt":21,"email":85},"Claudia Jaensch, MD, PhD","Claudia.Jaensch@goedstrup.rm.dk",{"facility":87,"status":70,"city":88,"state":72,"zip":89,"country":74,"countryCode":75,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Regional Hospital Randers","Randers","8930",{"type":77,"coordinates":91},[92,93],10.03639,56.4607,{"lat":93,"lon":92},[96],{"name":97,"role":60,"phone":21,"phoneExt":21,"email":98},"Jesper B Nors, MD, PhD","jenors@rm.dk",{"facility":50,"status":70,"city":100,"state":101,"zip":102,"country":74,"countryCode":75,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"Aalborg","North Denmark","9000",{"type":77,"coordinates":104},[105,106],9.9187,57.048,{"lat":106,"lon":105},[109],{"name":110,"role":60,"phone":21,"phoneExt":21,"email":111},"Lene Hjerrild Iversen, MD, PhD","lene.h.iversen@rn.dk",{"facility":113,"status":70,"city":114,"state":115,"zip":116,"country":74,"countryCode":75,"cosmosGeoPoint":117,"geoPoint":121,"contacts":122},"Odense University Hospital","Odense","The Region of Southern Denmark","5000",{"type":77,"coordinates":118},[119,120],10.38831,55.39594,{"lat":120,"lon":119},[123],{"name":124,"role":60,"phone":21,"phoneExt":21,"email":125},"Per Vadgaard Andersen, MD, PhD","Per.vadgaard.andersen@rsyd.dk",{"facility":127,"status":70,"city":128,"state":115,"zip":129,"country":74,"countryCode":75,"cosmosGeoPoint":130,"geoPoint":134,"contacts":135},"Svendborg Sygehus","Svendborg","5700",{"type":77,"coordinates":131},[132,133],10.60677,55.05982,{"lat":133,"lon":132},[136],{"name":124,"role":60,"phone":21,"phoneExt":21,"email":125},{"facility":47,"status":70,"city":138,"state":21,"zip":139,"country":74,"countryCode":75,"cosmosGeoPoint":140,"geoPoint":144,"contacts":145},"Aarhus","8000",{"type":77,"coordinates":141},[142,143],10.21076,56.15674,{"lat":143,"lon":142},[146],{"name":147,"role":60,"phone":21,"phoneExt":21,"email":148},"Peter Christensen, MD, PhD","petchris@rm.dk",{"facility":150,"status":70,"city":151,"state":21,"zip":152,"country":74,"countryCode":75,"cosmosGeoPoint":153,"geoPoint":157,"contacts":158},"Bispebjerg Hospital","Copenhagen","2400",{"type":77,"coordinates":154},[155,156],12.56553,55.67594,{"lat":156,"lon":155},[159],{"name":160,"role":60,"phone":21,"phoneExt":21,"email":161},"Nis Hallundbæk Schlesinger","Nis.Hallundbaek.Schlesinger@regionh.dk",{"facility":163,"status":70,"city":164,"state":21,"zip":165,"country":74,"countryCode":75,"cosmosGeoPoint":166,"geoPoint":170,"contacts":171},"Regional Hospital Horsens","Horsens","8700",{"type":77,"coordinates":167},[168,169],9.85034,55.86066,{"lat":169,"lon":168},[172],{"name":173,"role":60,"phone":21,"phoneExt":21,"email":174},"Kåre Gotschalck, MD, Ph.D","kaarsune@rm.dk",{"facility":176,"status":70,"city":177,"state":21,"zip":178,"country":74,"countryCode":75,"cosmosGeoPoint":179,"geoPoint":183,"contacts":184},"Regional Hospital Viborg","Viborg","8800",{"type":77,"coordinates":180},[181,182],9.40201,56.45319,{"lat":182,"lon":181},[185],{"name":186,"role":60,"phone":21,"phoneExt":21,"email":187},"Anders Tøttrup, MD, PhD","uffescho@rm.dk",{"type":44,"investigatorFullName":189,"investigatorTitle":190,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"Claus Lindbjerg Andersen","Professor, Group Leader",[192,193,194,195,197,199,200,201,203,204,206],{"name":47,"class":6},{"name":50,"class":6},{"name":55,"class":6},{"name":196,"class":6},"Randers Regional Hospital",{"name":198,"class":6},"Viborg Regional Hospital",{"name":69,"class":6},{"name":113,"class":6},{"name":202,"class":6},"Herlev Hospital",{"name":150,"class":6},{"name":205,"class":6},"Sygehus Lillebaelt",{"name":207,"class":6},"Svendborg Hospital","100563321","response-colorectal-cancer-survivors-follow-up-care---now-digital-and-need-based-100563321",false,"NCT06614647","RESPONSE: Colorectal Cancer Survivors' Follow-up Care - Now Digital and Need-based","RESPONSE: Colorectal Cancer Survivors' Follow-up Care - Now Digital and Need-based: A National Interventional Effectiveness Trial for Stage I and II Patients","RESPONSE","Inclusion Criteria:\n\n1. Patients treated for stage I and low risk stage II colorectal cancer with curative intend.\n2. Age 18 years or older.\n3. Understands spoken and written Danish language.\n4. Able to use digital care-guide as smartphone application.\n5. The patient is also included in DANISH.MRD part 1.\n\nExclusion Criteria:\n\n1. Patients who are unlikely to comply with the protocol, unable to return for subsequent visits and\u002For otherwise considered by the PIs to be unlikely to complete the study.\n2. Patients who are not able or willing to adhere to the digital platform.\n3. Patients treated only with local endoscopic resection, e.g.,Transanal Endoscopic microsurgery (TEM).","ALL","18 Years",{"count":219,"type":220},400,"ESTIMATED","INTERVENTIONAL",[223],"NA","Over the last decades, the 3-year recurrence rates for patients with stage I and II colorectal cancer have decreased to just 5% and 12%. The follow-up program offered to stage I and low-risk stage II patients has not changed accordingly and is still focused solely on recurrence detection. Moreover, it is a one-size-fits-all program, i.e. most of the follow-up resources are spent on non-recurrence patients who do not benefit.\n\nUp to 50% of cancer survivors suffer from reduced quality of life related to fear of cancer recurrence, treatment-related psychological distress, and\u002For severe late adverse effects of a biopsychosocial and\u002For organ-specific origin. Today many of these symptoms can be treated effectively. However, no systematic program aimed at monitoring and addressing the symptoms has been implemented yet.\n\nThe current project is testing a newly developed, digitally managed, patient-centered follow-up program that focuses on individual patient needs, including fear of cancer recurrence, psychological well-being, management of late adverse effects, and recurrence surveillance. This new program will be compared to the current standard of care in a national network of 11 colorectal cancer surgical centers in four of five Danish regions.\n\nPatients in the intervention group will receive the following:\n\n1. Risk-stratified circulating tumor DNA (ctDNA) guided recurrence surveillance.\n2. Late adverse effects monitoring with electronic patient-reported outcome measures, which are validated questionnaires that can identify and qualify late adverse effects.\n3. Systematic treatment for organ-specific and\u002For biopsychosocial late adverse effects.\n4. A digital care guide, to support the patient trajectory through the follow-up program, as a smartphone app.\n\nPatients in the standard group will receive standard-of-care follow-up.\n\nThe primary study endpoint will be the difference in health-related quality of life between the intervention and standard group. Secondary outcomes include e.g., comparison of health-related costs, differences in fear of cancer recurrence, recurrence-free survival, and patient satisfaction.\n\nThe investigators expect the new follow-up program to be better than the standard-of-care program in terms of the primary endpoint - quality of life - without compromising recurrence detection, and without increasing costs.",[226,227,228],"Colorectal Cancer","Quality of Life","Survivorship",[230,231,232],"Circulating Tumor DNA","Organ-specific late effects","Biopsychosocial Late effects","2026-04-28",{"date":235,"type":236},"2026-05-04","ACTUAL",{"date":238,"type":236},"2024-09-15",{"date":240,"type":220},"2030-02-01",{"name":5,"class":6},9]